ClinicalTrials.gg
CompletedNCT05813912Updated Jun 3, 2026Results posted

A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes

A Phase 3 interventional study of Insulin Icodec and Semaglutide in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 39 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
148
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
13th of 27
148 · median 84
Started
2023
with 2 others
Phase 3
9 of 27
none open now
Registered
22nd of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one is the 13th largest by enrollment, is one of 3 that started in 2023, is one of 9 in phase 3, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study looks at how a new medicine insulin icodec helps in reducing blood sugar levels when given along with semaglutide in patients with type 2 diabetes. Participants will get the medicine insulin icodec once a week in the first part of the study (run-in period-26 weeks). Participants will only enter the second part of the study if the blood sugar levels have not reduced to normal. If blood sugar levels are normal after the first 26 weeks, participants will continue in a 5-week follow up period. In the second part of the study (intensification period-26 weeks), participants will get both insulin icodec and semaglutide once weekly after which they will continue in a 5-week follow up period. Participants will have to inject the study medicines once a week on the same day of the week in a skin fold in the thigh, upper arm or stomach. The study will last for about 13 months. Participants will get a blood glucose meter to check blood sugar levels. In addition, participants will be asked to enter blood sugar levels in the study phone. In addition, Participants will be asked to enter selected few blood sugar values (three times during the study) in a paper diary that will be provided to participants. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with type 2 diabetes (T2D) greater than or equal to (>=) 180 days prior to the day of screening
  • from 7.5%-10.5% (58-91 millimoles per mole [mmol/mol]) (both inclusive)
  • Treated with once daily or twice daily basal insulin (minimum of 0.25 international units per kilograms per day (IU/kg/day) or 20 IU/day) without concomitant glucagon-like peptide-1 receptor agonists (GLP-1 RA) >= 90 days prior to the day of screening with or without any of the following antidiabetic drugs/regimens with stable doses >= 90 days prior to screening: metformin, sulfonylureas, meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose Cotransporter-2 (SGLT2) inhibitors, thiazolidinediones, alpha-glucosidase inhibitors. Oral combination products (for the allowed individual oral anti-diabetic drugs)

Exclusion criteria

Exclusion Criteria:

  • Presence or history of pancreatitis (acute or chronic) within 180 days before screening
  • Myocardial infarction, stroke, hospitalisation for unstable angina pectoris or within 180 days prior to the day of screening and between screening and initiation
  • Chronic heart failure classified as being in (NYHA) Class IV at screening
  • Planned coronary, carotid or peripheral artery revascularization
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and initiation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Insulin Icodec + Semaglutide

    Participants will receive insulin icodec once weekly for 26 weeks in run-in period to ensure the dose optimization. Thereafter, participants meeting intensification criteria will proceed to the 26-week treatment period to receive once weekly semaglutide subcutaneously starting from 0.25 milligrams (mg) and dose increased up to 1 mg along with 700 units per milliliter (U/mL) insulin icodec therapy. There are no maximum or minimum insulin doses.

    Drug: Insulin Icodec · Drug: Semaglutide

Interventions

  • Participants will receive subcutaneously insulin icodec once weekly for 52 weeks.

  • Participants will receive once weekly semaglutide subcutaneously starting from 0.25 mg and dose increased up to 1 mg for 26 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change in HbA1c (percentage) from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.

    Time frame: Baseline (Week 26), Week 52

Secondary outcomes

  1. Change in Mean 7-point Self-measured Plasma Glucose (SMPG) Profiles

    Change in mean 7-point SMPG profiles from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.

    Time frame: Baseline (Week 26), Week 52

  2. Change in Mean Post-prandial Glucose Increment (Over All Meals)

    Change in mean post-prandial glucose increment from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.

    Time frame: Baseline (Week 26), Week 52

  3. Change in Fasting Plasma Glucose (FPG)

    Change in FPG from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.

    Time frame: Baseline (Week 26), Week 52

  4. Number of Severe Hypoglycaemic Episodes (Level 3)

    Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).

    Time frame: From baseline (week 26) to week 57

  5. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 Milligrams Per Deciliter {mg/dL}], Confirmed by Blood Glucose [BG] Meter)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).

    Time frame: From baseline (week 26) to week 57

  6. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L [54 mg/dL]), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).

    Time frame: From baseline (week 26) to week 57

  7. Change in Body Weight

    Change in body weight from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).

    Time frame: Baseline (Week 26), Week 52

  8. Relative Change in Weekly Insulin Icodec Dose

    Relative change in weekly insulin icodec dose from week 25 to week 52 is presented.

    Time frame: From week 25 to week 52

07

Results

Posted Jun 3, 2026

Participant flow

The trial was conducted in 5 countries as follows: Poland, Serbia, Czechia, Malaysia and Thailand.

Run-in Period (Week 0 to Week 26)
Participant flow — Run-in Period (Week 0 to Week 26)
MilestoneInsulin Icodec + Semaglutide
Started148
Exposed148
Safety analysis set (sas)148
Completed94
Not completed54
Withdrew: Failing to meet intensification requirements51
Withdrew: Withdrawal by subject1
Withdrew: Physician decision1
Withdrew: Death1
Treatment Period (Week 26 to Week 52)
Participant flow — Treatment Period (Week 26 to Week 52)
MilestoneInsulin Icodec + Semaglutide
Started94
Exposed94
Full analysis set (fas)94
Completed91
Not completed3
Withdrew: Failing to meet intensification requirements1
Withdrew: Withdrawal by subject1
Withdrew: Lost to follow-up1

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change in HbA1c (percentage) from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.

Time frame:
Baseline (Week 26), Week 52
Reported as:
Mean · Percentage (%) of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage (%) of HbA1cInsulin Icodec + Semaglutide
Change in Glycated Haemoglobin (HbA1c)-1.23 ± 0.86
Statistical analysis
  • Insulin Icodec + Semaglutide · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -1.23 · 95% CI -1.39 to -1.07
SecondaryChange in Mean 7-point Self-measured Plasma Glucose (SMPG) Profiles

Change in mean 7-point SMPG profiles from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.

Time frame:
Baseline (Week 26), Week 52
Reported as:
Mean · millimoles per liter (mmol/L)
Change in Mean 7-point Self-measured Plasma Glucose (SMPG) Profiles
millimoles per liter (mmol/L)Insulin Icodec + Semaglutide
Change in Mean 7-point Self-measured Plasma Glucose (SMPG) Profiles-1.69 ± 2.42
SecondaryChange in Mean Post-prandial Glucose Increment (Over All Meals)

Change in mean post-prandial glucose increment from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.

Time frame:
Baseline (Week 26), Week 52
Reported as:
Mean · mmol/L
Change in Mean Post-prandial Glucose Increment (Over All Meals)
mmol/LInsulin Icodec + Semaglutide
Change in Mean Post-prandial Glucose Increment (Over All Meals)-1.27 ± 2.17
SecondaryChange in Fasting Plasma Glucose (FPG)

Change in FPG from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the on-intensification phase. On-intensification phase was observed data at planned visits from time of the intensification week 26 until the end of treatment week 52, i.e., for participants who permanently discontinued either insulin icodec or semaglutide treatment, post-discontinuation observations were not included.

Time frame:
Baseline (Week 26), Week 52
Reported as:
Mean · mmol/L
Change in Fasting Plasma Glucose (FPG)
mmol/LInsulin Icodec + Semaglutide
Change in Fasting Plasma Glucose (FPG)-1.29 ± 2.24
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Number of severe hypoglycaemic episodes (level 3) is presented. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).

Time frame:
From baseline (week 26) to week 57
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin Icodec + Semaglutide
Number of Severe Hypoglycaemic Episodes (Level 3)0
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 Milligrams Per Deciliter {mg/dL}], Confirmed by Blood Glucose [BG] Meter)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of (\<) 3.0 mmol/L (54 mg/dL) confirmed by BG meter. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).

Time frame:
From baseline (week 26) to week 57
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 Milligrams Per Deciliter {mg/dL}], Confirmed by Blood Glucose [BG] Meter)
EpisodesInsulin Icodec + Semaglutide
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than [<] 3.0 mmol/L [54 Milligrams Per Deciliter {mg/dL}], Confirmed by Blood Glucose [BG] Meter)13
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L [54 mg/dL]), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)

Number of clinically significant hypoglycaemic episodes (level 2) (\<3.0 mmol/L (54 mg/dL), confirmed by BG meter) or severe hypoglycaemic episodes (level 3) is presented. Clinically significant hypoglycaemia (level 2) is defined as plasma glucose value of \< 3.0 mmol/L (54 mg/dL) confirmed by BG meter. Severe hypoglycaemia (level 3) is defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).

Time frame:
From baseline (week 26) to week 57
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L [54 mg/dL]), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesInsulin Icodec + Semaglutide
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L [54 mg/dL]), Confirmed by BG Meter) or Severe Hypoglycaemic Episodes (Level 3)13
SecondaryChange in Body Weight

Change in body weight from baseline (week 26) to week 52 is presented. The outcome data was evaluated based on the Treatment-phase-on-treatment period. The Treatment-phase-on-treatment period was all observed data from time of the intensification week 26 until 6 weeks after last date of either insulin icodec or semaglutide treatment (whichever comes last).

Time frame:
Baseline (Week 26), Week 52
Reported as:
Mean · Kilograms (Kg)
Change in Body Weight
Kilograms (Kg)Insulin Icodec + Semaglutide
Change in Body Weight-3.85 ± 3.98
SecondaryRelative Change in Weekly Insulin Icodec Dose

Relative change in weekly insulin icodec dose from week 25 to week 52 is presented.

Time frame:
From week 25 to week 52
Reported as:
Least squares mean · Insulin Units per Week
Relative Change in Weekly Insulin Icodec Dose
Insulin Units per WeekInsulin Icodec + Semaglutide
Relative Change in Weekly Insulin Icodec Dose0.76 (0.72 to 0.81)

Adverse events

Collected over Week 0 to week 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Icodec: Run-in Period1/148 (0.7%)7/148 (4.7%)14/148 (9.5%)
Insulin Icodec + Semaglutide: Treatment Period0/94 (0%)3/94 (3.2%)50/94 (53.2%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventIcodec: Run-in PeriodInsulin Icodec + Semaglutide: Treatment Period
HydroceleCongenital, familial and genetic disorders0/1481/94
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1481/94
OsteoarthritisMusculoskeletal and connective tissue disorders0/1481/94
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/1481/94
PhimosisCongenital, familial and genetic disorders1/1480/94
Angina PectorisCardiac disorders1/1480/94
GangreneInfections and infestations1/1480/94
Anticoagulation Drug Level IncreasedInvestigations1/1480/94
Metastases To LiverNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1480/94
Rectal CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1480/94
Most frequent other events
Most frequent other events
EventIcodec: Run-in PeriodInsulin Icodec + Semaglutide: Treatment Period
NauseaGastrointestinal disorders0/14818/94
VomitingGastrointestinal disorders0/1488/94
Upper respiratory tract infectionInfections and infestations6/1487/94
Decreased appetiteMetabolism and nutrition disorders0/1486/94
DyspepsiaGastrointestinal disorders0/1486/94
Diabetic RetinopathyEye disorders8/1480/94
HyperkalaemiaMetabolism and nutrition disorders0/1485/94

Baseline characteristics

Safety analysis set (SAS) included all participants who were exposed to investigational intervention (s).

Age, Continuous
Age, Continuous(Years)Insulin Icodec + Semaglutide
Mean60.11 ± 9.75
Sex: Female, Male
Sex: Female, Male(Participants)Insulin Icodec + Semaglutide
Female68
Male80
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Insulin Icodec + Semaglutide
Hispanic or Latino0
Not Hispanic or Latino148
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Insulin Icodec + Semaglutide
American Indian or Alaska Native0
Asian40
Native Hawaiian or Other Pacific Islander0
Black or African American0
White108
More than one race0
Unknown or Not Reported0
08

Study locations

39 sites
  • Edumed Broumov
    Broumov, 550 01, Czechia
  • DIAMIN
    Chrudim, 537 01, Czechia
  • Diabetologické centrum s.r.o.
    Olomouc, 779 00, Czechia
  • DIALINE s.r.o.
    Plzeň 3, 301 00, Czechia
  • Diabet2 s.r.o.
    Prague, 110 00, Czechia
  • Medicon a.s.
    Prague, 140 00, Czechia
  • Diabetologická a endokrinologická ambulance Praha
    Prague, 140 21, Czechia
  • EUC Klinika Praha a.s.
    Prague, 150 00, Czechia
  • Comfort Care Praha s.r.o.
    Praha 4 - Chodov, 148 00, Czechia
  • DiaPodi care s.r.o.
    Soběslav I, 39201, Czechia
  • Hospital Canselor Tuanku Muhriz UKM
    Cheras, Kuala Lumpur 56000, Malaysia
  • Hospital Seri Manjung
    Seri Manjung, Perak 32040, Malaysia
  • Hospital Putrajaya
    Putrajaya, Putrajaya 62250, Malaysia
  • Hospital Miri
    Miri, Sarawak 98000, Malaysia
  • Universiti Teknologi MARA, Sungai Buloh Campus
    Sungai Buloh, Selangor 47000, Malaysia
  • Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
    Krakow, Lesser Poland Voivodeship 31-261, Poland
  • Metabolica Sp. z o.o.
    Tarnów, Lesser Poland Voivodeship 33-100, Poland
  • Osrodek Badan Klinicznych "METABOLICA" lek. Robert Witek
    Tarnów, Lesser Poland Voivodeship 33-100, Poland
  • Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski
    Gorzów Wielkopolski, Lubusz Voivodeship 66-400, Poland
  • NBR Polska
    Warsaw, Masovian Voivodeship 00-710, Poland
  • Osteo-Medic s.c. A. Racewicz, J. Supronik
    Bialystok, 15-351, Poland
  • Centrum Badan Klinicznych PI-House Sp. z o.o.
    Gdansk, 80-546, Poland
  • NZOZ Gdanska Poradnia Cukrzycowa Sp.z o.o.
    Gdansk, 80-858, Poland
  • NZOZ Gdanska Poradnia Cukrzycowa
    Gdansk, 80-858, Poland
  • Specjalistyczny Gabinet Diabetologiczny Radoslaw Rumianowski
    Gorzów Wielkopolski, 66-400, Poland
  • Centrum Medyczne Pratia Katowice
    Katowice, 40-081, Poland
  • Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
    Lodz, 90-302, Poland
  • NBR Polska Tomasz Klodawski
    Warsaw, 00-710, Poland
  • Poradnia Chorob Metabolicznych w Wierzchoslawicach
    Wierzchosławice, 33-122, Poland
  • Wojewodzka Poradnia dla Chorych na Cukrzyce w Zabrzu
    Zabrze, 41-800, Poland
  • Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
    Lodz, Łódź Voivodeship 90-302, Poland
  • Clin. Centre Vojvodina, Clin. endocr., diab. and met. dis.
    Novi Sad, Vojvodina 21000, Serbia
  • CHC Zvezdara, Clinical department for endocrinology
    Belgrade, 11000, Serbia
  • Clinical Hospital Centre Zemun
    Belgrade, 11080, Serbia
  • Clinical Centre Kragujevac, Internal Diseases Clinic, Endocrinology department
    Kragujevac, 34000, Serbia
  • King Chulalongkorn Memorial Hospital
    Bangkok, 10330, Thailand
  • Rajavithi Hospital_Diabetes and Endocrinology
    Bangkok, 10400, Thailand
  • Rajavithi Hospital
    Bangkok, 10400, Thailand
  • Ramathibodi Hospital - Ped-Endo and Metabolism
    Bangkok, 10400, Thailand
09

References and documents

Publications

  • Strojek K, Liebl A, Mumbaikar NN, Sogaard SB, Kehlet Watt S, Philis-Tsimikas A. Efficacy and Safety of Intensifying Once-Weekly Insulin Icodec Treatment With Once-Weekly Semaglutide in Adults With Type 2 Diabetes: A Single-Arm, Open-Label, Treat-to-Target, Phase 3b Trial (ONWARDS 8). Diabetes Obes Metab. 2026 Jul 1. doi: 10.1111/dom.71049. Online ahead of print. PubMed 42387310 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Apr 2025, 18 months.

Results were first posted in Jun 2026, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 18 months is close to that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2023
First posted
Apr 14, 2023
StartActual
Sep 22, 2023
Primary completionActual
Apr 14, 2025
CompletionActual
May 16, 2025
Results first posted
Jun 3, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05813912
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 14, 2023
Start date
Sep 22, 2023
Primary completion
Apr 14, 2025
Completion
May 16, 2025
Results posted
Jun 3, 2026
Last update
Jun 3, 2026

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin icodec · Semaglutide

Start the discussion